Literature DB >> 23458769

Clinical relevance of the ESKAPE pathogens.

Jack N Pendleton1, Sean P Gorman, Brendan F Gilmore.   

Abstract

In recent years, the Infectious Diseases Society of America has highlighted a faction of antibiotic-resistant bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) - acronymically dubbed 'the ESKAPE pathogens' - capable of 'escaping' the biocidal action of antibiotics and mutually representing new paradigms in pathogenesis, transmission and resistance. This review aims to consolidate clinically relevant background information on the ESKAPE pathogens and provide a contemporary summary of bacterial resistance, alongside pertinent microbiological considerations necessary to face the mounting threat of antimicrobial resistance.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23458769     DOI： 10.1586/eri.13.12

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


  374 in total

1.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Investigation of the molecular epidemiology of Acinetobacter baumannii isolated from patients and environmental contamination.

Authors:  Chunmei Ying; Yongli Li; Yaping Wang; Bing Zheng; Chengde Yang
Journal:  J Antibiot (Tokyo)       Date:  2015-04-15       Impact factor: 2.649

3.  A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.

Authors:  Madeline R Galac; Erik Snesrud; Francois Lebreton; Jason Stam; Michael Julius; Ana C Ong; Rosslyn Maybank; Anthony R Jones; Yoon I Kwak; Kate Hinkle; Paige E Waterman; Emil P Lesho; Jason W Bennett; Patrick Mc Gann
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

4.  Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa.

Authors:  Veerle Liebens; Valerie Defraine; Wouter Knapen; Toon Swings; Serge Beullens; Romu Corbau; Arnaud Marchand; Patrick Chaltin; Maarten Fauvart; Jan Michiels
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Toward a clinical antifungal peptoid: Investigations into the therapeutic potential of AEC5.

Authors:  Sabrina K Spicer; Aarthi Subramani; Angelica L Aguila; R Madison Green; Erin E McClelland; Kevin L Bicker
Journal:  Biopolymers       Date:  2019-04-02       Impact factor: 2.505

6.  ClyJ Is a Novel Pneumococcal Chimeric Lysin with a Cysteine- and Histidine-Dependent Amidohydrolase/Peptidase Catalytic Domain.

Authors:  Hang Yang; Yujing Gong; Huaidong Zhang; Irina Etobayeva; Paulina Miernikiewicz; Dehua Luo; Xiaohong Li; Xiaoxu Zhang; Krystyna Dąbrowska; Daniel C Nelson; Jin He; Hongping Wei
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

7.  An essential Staphylococcus aureus cell division protein directly regulates FtsZ dynamics.

Authors:  Prahathees J Eswara; Robert S Brzozowski; Marissa G Viola; Gianni Graham; Catherine Spanoudis; Catherine Trebino; Jyoti Jha; Joseph I Aubee; Karl M Thompson; Jodi L Camberg; Kumaran S Ramamurthi
Journal:  Elife       Date:  2018-10-02       Impact factor: 8.140

8.  α-Tocopherol Attenuates the Severity of Pseudomonas aeruginosa-induced Pneumonia.

Authors:  Brant M Wagener; Naseem Anjum; Cilina Evans; Angela Brandon; Jaideep Honavar; Judy Creighton; Maret G Traber; Robert L Stuart; Troy Stevens; Jean-Francois Pittet
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

Review 9.  Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis.

Authors:  Elio Rossi; Ruggero La Rosa; Jennifer A Bartell; Rasmus L Marvig; Janus A J Haagensen; Lea M Sommer; Søren Molin; Helle Krogh Johansen
Journal:  Nat Rev Microbiol       Date:  2020-11-19       Impact factor: 60.633

10.  Role of Pseudomonas aeruginosa AmpR on β-lactam and non-β-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics.

Authors:  Hansi Kumari; Deepak Balasubramanian; Diansy Zincke; Kalai Mathee
Journal:  J Med Microbiol       Date:  2014-01-25       Impact factor: 2.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.